comparemela.com

Latest Breaking News On - Hutchison china meditech - Page 1 : comparemela.com

Hepatocellular Carcinoma Drugs (PD-1/PD-L1 Inhibitors,

Fidelity FCSS: 11% cumulative 3 year NAV growth to Dec 2022 - DirectorsTalk Interviews

HUTCHMED (NASDAQ:HCM) Downgraded by Zacks Investment Research to Hold

Zacks Investment Research lowered shares of HUTCHMED (NASDAQ:HCM – Get Rating) from a buy rating to a hold rating in a research report released on Thursday, Zacks.com reports. According to Zacks, “Hutchison China MediTech Limited researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. The Company offers drugs for oncology and autoimmune diseases treatment. […]

HUTCHMED (NASDAQ:HCM) Upgraded to Buy by Zacks Investment Research

Zacks Investment Research upgraded shares of HUTCHMED (NASDAQ:HCM – Get Rating) from a hold rating to a buy rating in a research note released on Wednesday, Zacks.com reports. The brokerage currently has $15.00 price objective on the stock. According to Zacks, “Hutchison China MediTech Limited researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.